点击上方“公众号”可订阅哦!兴业证券医药小组近期,我们发布了《医药生物行业2026年年度策略:创新迈入新篇章,国际化驶向新征程》,欢迎阅读^^投资要点:“创新+国际化”仍将是2026年板块核心主线。重点关注产业趋势持续向好的创新药,全球竞争力持续加强+出海持续落地+商业化盈利兑现。重点关注创新药产业链,景气度预计将持续向上。同时,医疗器械行业阶段性影响因素持续缓和,创新与国际化加速推进,2026年...
Source Link点击上方“公众号”可订阅哦!兴业证券医药小组近期,我们发布了《医药生物行业2026年年度策略:创新迈入新篇章,国际化驶向新征程》,欢迎阅读^^投资要点:“创新+国际化”仍将是2026年板块核心主线。重点关注产业趋势持续向好的创新药,全球竞争力持续加强+出海持续落地+商业化盈利兑现。重点关注创新药产业链,景气度预计将持续向上。同时,医疗器械行业阶段性影响因素持续缓和,创新与国际化加速推进,2026年...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.